Brind.

Ultragenyx Pharmaceutical achieved compliance with Nasdaq Listing Rule 5635(c)(4) on August 22, 2025.

3 reports, 1 independent Updated Jul 1
Gone quiet
Reports
3
Developments
4
Repetition
33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Ultragenyx Pharmaceutical achieved compliance with Nasdaq Listing Rule 5635(c)(4) on August 22, 2025.

Who's involved

What this event is mainly about
Ultragenyx Pharmaceutical

How it developed

Newest first. Tap a step to see who reported it.
  1. Ultragenyx Pharmaceutical must file required documents regarding its NASDAQ company status with the SEC.Sub-event
  2. Ultragenyx Pharmaceutical reported a grant under Nasdaq listing rules on June 21, 2025.Sub-event
  3. Compliance achieved for Ultragenyx Pharmaceutical with Nasdaq Listing Rule 5635(c)(4) on 2025-08-22.1 source
  4. Ultragenyx achieved compliance with Nasdaq Listing Rule 5635(c)(4) on July 19, 2025.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NOVATO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company f
  • GlobeNewswireUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NOVATO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company f
1 more outlet ran the same wire story